Study overview
For participants
Crohn’s disease: SAR441566 study
Worum geht es in dieser Studie? Dies ist eine minimalinterventionelle, offene und randomisierte Studie, in der zwei in Deutschland zugelassene Therapien bei Erwachsenen mit neu diagnostizierter mittelschwerer bis schwerer Colitis ulcerosa verglichen werden: die...
Crohn’s disease: SAR441566 study
Worum geht es in dieser Studie? Dies ist eine Phase-3-Studie, in der die Wirksamkeit und Sicherheit eines neuen Medikaments namens JNJ-78934804 bei Erwachsenen mit mittelschwerem bis schwerem Morbus Crohn untersucht wird. JNJ-78934804 kombiniert zwei bereits...
Crohn’s disease: SAR441566 study
Worum geht es in dieser Studie? Dies ist eine Phase-3-Studie, in der die Wirksamkeit und Sicherheit eines neuen Medikaments namens JNJ-78934804 bei Erwachsenen mit mittelschwerem bis schwerem Morbus Crohn untersucht wird. JNJ-78934804 kombiniert zwei bereits...
Crohn’s disease: SAR441566 study
What is this study about? This is a Phase 2 study examining the efficacy and safety of a new drug called SAR441566 in adults with moderate to severe Crohn's disease. Various dosages of SAR441566 are compared to a placebo (sham drug) to determine which works best. Who...
Crohn’s disease: FORTIFY study (Risankizumab)
This comprehensive study includes several sub-studies to evaluate various aspects of Risankizumab treatment, including maintenance therapy, long-term safety, and patient-reported outcomes. Open-label extensions ensure continuous care for participants.
Crohn’s disease: GRAVITI study (Guselkumab as subcutaneous therapy)
This study examines the safety and efficacy of guselkumab as a subcutaneous (injected under the skin) therapy for people with Crohn's disease.
Crohn’s disease: DUET-CD study (combination of guselkumab and golimumab)
Similar to ulcerative colitis, this study tests the combination of the two drugs for Crohn's disease and compares it with the single application. The aim is to determine which therapy works best after 48 weeks.
Ulcerative colitis: DUET-UC study (combination of guselkumab and golimumab)
This study examines the efficacy and safety of combining the two medications guselkumab and golimumab compared to using each medication individually. The study is aimed at patients with moderate to severe ulcerative colitis who have not had success with other advanced...
Ulcerative colitis: COMMAND Study (Risankizumab)
This study focuses on the drug risankizumab. It examines various phases, including a 52-week maintenance phase and open-label extensions, to assess safety and efficacy in patients who have previously responded to risankizumab. For patients who benefit from the...
Ulcerative colitis: ABTECT Maintenance Study
This study tests the long-term safety and efficacy of the drug ABX464, taken once daily as maintenance therapy. It is aimed at patients who have not responded to other treatments—both conventional and advanced therapies—have lost their effect, or have not tolerated...
